Cannasan Research Institute and Cannasan Products

Ing. František Bednařík

Healing effects of Cannabis Sativa have been known for thousands of years and many researches confirm these effects. In recent years intensity of research on therapeutic effects of this plant has increased. Knowledge of both its chemical composition and its pharmacokinetic have been deepened and the latter is very critical for understanding effects of substances contained in cannabis on the organism.

More than 1,400 chemical substances have been found in cannabis plants, of which 144 are so-called cannabinoids. Only one of these substances – THC – is a psychoactive substance. Amount of THC in cannabis treatment affects patient’s mental condition and consequently limits widespread use of cannabis therapeutic effects, especially in work-active patients.

In human medicine, just cannabis strains with higher THC content are currently used for treatment. At the same time their high THC content limits number of patients being treated due to their psychogenic effects.

Cannabis strains with low THC, i.e. up to 0.3% in dry matter, are technologically used in pharmaceutical industry to produce CBD or CBG. The goal of our research was to find out possibilities of using low THC cannabis strains to treat various diseases.

Our research has shown that by reducing amount of THC (psychogenic component) to thousandths per mill, any psychogenic effect is completely eliminated; on the contrary this low THC level significantly stimulates immune system of the organism. Healing potential of other substances contained in cannabis remains (entourage effect).

In 2015, we have developed a completely new approach for cannabis processing for medical use. This new method is based, among other things, on a combination of active ingredients from hemp and medicinal plants. By combining active substances of selected types of medicinal plants and substances contained in cannabis, we have achieved positive, objective and curative results in treatment of a wide range of diseases.

In 2015 and 2016, this method of cannabis treatment was applied to a large group of patients with different diagnoses. The results show an extraordinary potential of using this method of phytotherapy in human medicine, especially in chronic diseases.

By removing psychogenic effects of our cannabis preparation, it is possible to administer this product to patients for whom cannabis treatment has not yet been suitable (drivers, teachers, police officers, firefighters, doctor and others).

The preparation was named Cannasan (Cannabis sativa nuovum).

It is administered orally.

Cannasan is a mixture of hydrophilic and lipophilic extracts, infusions and macerates of cannabis sativa and selected types of medicinal plants, insoluble fiber and vegetable oils.

In 2017, at the international scientific conferences in Ljubljana and in Prague, the results of use of the preparation by 260 patients with 43 indifferent diagnoses were presented.

In 2017 and 2018, effects of Cannasan were verified in 850 patients. In more than 86% of patients with a total of 63 different diagnoses a successful therapeutic effect has been achieved.

Cannasan is a proven and verified cannabis-based preparation, with no psychogenic effects, with a standardized active ingredients content, intended mainly for treatment of chronic diseases.

Cannasan treatment requires significantly lower total cost than conventional treatment, or than treatment with so-called therapeutic hemp. Hence, Cannasan is an effective and economically viable option for cannabis treatment for a very large group of patients.

Evidently objective curative effects have been achieved in the following groups of diseases:

  • neurodegenerative disorders – multiple sclerosis, Parkinson’s disease, myasthenia gravis, Alzheimer’s disease …
  • autoimmune diseases – rheumatoid arthritis, joint arthrosis…
  • dermatoses – psoriasis, atopic dermatitis…
  • metabolic disorders – type 2 diabetes, high cholesterol…
  • chronic idiopathic inflammation – lymph node inflammation…
  • venous ulcers, venous inflammation, carpal tunnel inflammation…
  • elimination of side effects of chemotherapy
  • stimulation of angioplasty – post-traumatic wound healing
  • gynaecological diseases – menstrual pain, endometriosis…
  • psychosomatic diseases – anxiety, migraines…
  • inflammatory bowel disease – ulcerative colitis, Crohn’s disease
  • diarrhea – indigestion, food allergy…
  • constipation – indigestion…
  • regeneration after surgery – bones and tissues adhesion
  • convalescence of patients after central stroke
  • pain – joints, chronic pain…
  • bedsores – in bedridden (paralyzed) patients
  • inflammations in the oral cavity – periodontitis…

We continue in implementation of preclinics (translation medicine) in number of medical workplaces in Czech Republic and abroad. We cooperate on further research and development with several universities and research institutes.